Ovid Therapeutics Stock Performance
| OVID Stock | USD 1.47 0.05 3.29% |
Ovid Therapeutics has a performance score of 1 on a scale of 0 to 100. The company holds a Beta of 2.54, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Ovid Therapeutics will likely underperform. Ovid Therapeutics right now holds a risk of 5.79%. Please check Ovid Therapeutics total risk alpha, expected short fall, market facilitation index, as well as the relationship between the value at risk and daily balance of power , to decide if Ovid Therapeutics will be following its historical price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Ovid Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain forward indicators, Ovid Therapeutics may actually be approaching a critical reversion point that can send shares even higher in March 2026. ...more
1 | Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer | 12/02/2025 |
2 | Disposition of 1250 shares by Takeda Pharmaceutical Co Ltd of Ovid Therapeutics subject to Rule 16b-3 | 12/08/2025 |
3 | Janus Henderson Group PLC Acquires Significant Stake in Ovid Therapeutics Inc - GuruFocus | 12/12/2025 |
4 | Disposition of tradable shares by Levin Jeremy M of Ovid Therapeutics subject to Rule 16b-3 | 12/15/2025 |
5 | Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 , OV350 Intravenous | 12/18/2025 |
6 | Wall Street Zen Upgrades Ovid Therapeutics to Hold - MarketBeat | 12/26/2025 |
7 | Acquisition by Margaret Alexander of 890000 shares of Ovid Therapeutics at 1.76 subject to Rule 16b-3 | 01/02/2026 |
8 | During J. P. Morgan Healthcare Week, Biotech Showcase Provides Private and Micro- to Mid-Cap Public Company Executives One-Stop Access to Investors, Pharma Part... | 01/08/2026 |
9 | Disposition of 34017 shares by Rakhit Amit of Ovid Therapeutics at 3.71 subject to Rule 16b-3 | 01/13/2026 |
10 | Ovid Therapeutics Bullish Post-PIPE With 2 Differentiated CNS Moonshots - Seeking Alpha | 01/26/2026 |
11 | Both retail investors who control a good portion of Ovid Therapeutics Inc. along with institutions must be dismayed after last weeks 11 percent decrease | 01/30/2026 |
12 | Ovid takes another big swing in neuroscience under a new CEO | 02/13/2026 |
| Begin Period Cash Flow | 29 M | |
| Total Cashflows From Investing Activities | 54.6 M |
Ovid Therapeutics Relative Risk vs. Return Landscape
If you would invest 150.00 in Ovid Therapeutics on November 25, 2025 and sell it today you would lose (3.00) from holding Ovid Therapeutics or give up 2.0% of portfolio value over 90 days. Ovid Therapeutics is currently generating 0.1281% in daily expected returns and assumes 5.7858% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of stocks are less volatile than Ovid, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ovid Therapeutics Target Price Odds to finish over Current Price
The tendency of Ovid Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.47 | 90 days | 1.47 | about 78.4 |
Based on a normal probability distribution, the odds of Ovid Therapeutics to move above the current price in 90 days from now is about 78.4 (This Ovid Therapeutics probability density function shows the probability of Ovid Stock to fall within a particular range of prices over 90 days) .
Ovid Therapeutics Price Density |
| Price |
Predictive Modules for Ovid Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Ovid Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Ovid Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Ovid Therapeutics is not an exception. The market had few large corrections towards the Ovid Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Ovid Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Ovid Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.15 | |
β | Beta against Dow Jones | 2.54 | |
σ | Overall volatility | 0.14 | |
Ir | Information ratio | 0.04 |
Ovid Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Ovid Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Ovid Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Ovid Therapeutics had very high historical volatility over the last 90 days | |
| Ovid Therapeutics may become a speculative penny stock | |
| Ovid Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 566 K. Net Loss for the year was (26.43 M) with profit before overhead, payroll, taxes, and interest of 6.61 M. | |
| Ovid Therapeutics currently holds about 152.37 M in cash with (55.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.16, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Ovid Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Ovid takes another big swing in neuroscience under a new CEO |
Ovid Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Ovid Stock often depends not only on the future outlook of the current and potential Ovid Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Ovid Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 70.9 M | |
| Cash And Short Term Investments | 53.1 M |
Ovid Therapeutics Fundamentals Growth
Ovid Stock prices reflect investors' perceptions of the future prospects and financial health of Ovid Therapeutics, and Ovid Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ovid Stock performance.
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (94.87) % | ||||
| Current Valuation | 92.37 M | ||||
| Shares Outstanding | 71.21 M | ||||
| Price To Earning | 1.11 X | ||||
| Price To Book | 2.09 X | ||||
| Price To Sales | 15.84 X | ||||
| Revenue | 566 K | ||||
| Gross Profit | 6.61 M | ||||
| EBITDA | (57.77 M) | ||||
| Net Income | (26.43 M) | ||||
| Cash And Equivalents | 152.37 M | ||||
| Cash Per Share | 2.16 X | ||||
| Total Debt | 14.76 M | ||||
| Debt To Equity | 0.10 % | ||||
| Current Ratio | 16.94 X | ||||
| Book Value Per Share | 0.63 X | ||||
| Cash Flow From Operations | (55.96 M) | ||||
| Earnings Per Share | (0.50) X | ||||
| Market Capitalization | 104.68 M | ||||
| Total Asset | 92.17 M | ||||
| Retained Earnings | (304.3 M) | ||||
| Working Capital | 45.42 M | ||||
| Current Asset | 74.21 M | ||||
| Current Liabilities | 5.13 M | ||||
About Ovid Therapeutics Performance
By analyzing Ovid Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Ovid Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Ovid Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ovid Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.26) | (0.27) | |
| Return On Capital Employed | (0.87) | (0.92) | |
| Return On Assets | (0.26) | (0.27) | |
| Return On Equity | (0.45) | (0.47) |
Things to note about Ovid Therapeutics performance evaluation
Checking the ongoing alerts about Ovid Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ovid Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ovid Therapeutics had very high historical volatility over the last 90 days | |
| Ovid Therapeutics may become a speculative penny stock | |
| Ovid Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 566 K. Net Loss for the year was (26.43 M) with profit before overhead, payroll, taxes, and interest of 6.61 M. | |
| Ovid Therapeutics currently holds about 152.37 M in cash with (55.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.16, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Ovid Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Ovid takes another big swing in neuroscience under a new CEO |
- Analyzing Ovid Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ovid Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Ovid Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ovid Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ovid Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ovid Therapeutics' stock. These opinions can provide insight into Ovid Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Ovid Stock analysis
When running Ovid Therapeutics' price analysis, check to measure Ovid Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ovid Therapeutics is operating at the current time. Most of Ovid Therapeutics' value examination focuses on studying past and present price action to predict the probability of Ovid Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ovid Therapeutics' price. Additionally, you may evaluate how the addition of Ovid Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |